Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data

被引:96
作者
Bauer, M. [1 ]
Zeitlinger, M. [1 ]
Karch, R. [2 ]
Matzneller, P. [1 ]
Stanek, J. [1 ]
Jaeger, W. [3 ]
Boehmdorfer, M. [3 ]
Wadsak, W. [4 ]
Mitterhauser, M. [4 ]
Bankstahl, J. P. [5 ]
Loescher, W. [5 ]
Koepp, M. [6 ]
Kuntner, C. [7 ]
Mueller, M. [1 ]
Langer, Oliver [1 ,7 ]
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[2] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[3] Univ Vienna, Dept Clin Pharm & Diagnost, Vienna, Austria
[4] Med Univ Vienna, Dept Nucl Med, Vienna, Austria
[5] Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Hannover, Germany
[6] UCL, Dept Clin & Expt Epilepsy, Inst Neurol, London, England
[7] AIT Austrian Inst Technol GmbH, Hlth & Environm Dept, Mol Med, Seibersdorf, Austria
基金
奥地利科学基金会;
关键词
P-GLYCOPROTEIN FUNCTION; POSITRON-EMISSION-TOMOGRAPHY; SPECIES-DIFFERENCES; INHIBITION; TRANSPORTERS; CYCLOSPORINE; LYMPHOCYTES; METABOLISM; EPILEPSY; XR9576;
D O I
10.1038/clpt.2011.217
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[C-11] verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects. We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology. Tariquidar was equipotent in humans and rats in its effect of increasing (R)-[C-11]verapamil brain uptake (expressed as whole-brain volume of distribution (V-T)), with very similar half-maximum-effect concentrations. Both in humans and in rats, brain V-T approached plateau levels at plasma tariquidar concentrations >1,000 ng/ml. However, Pgp inhibition in humans led to only a 2.7-fold increase in brain V-T relative to baseline scans (before administration of tariquidar) as compared with 11.0-fold in rats. The results of this translational study add to the accumulating evidence that there are marked species-dependent differences in Pgp expression and functionality at the BBB.
引用
收藏
页码:227 / 233
页数:7
相关论文
共 41 条
[1]   Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients [J].
Abrahim, Aiman ;
Luurtsema, Gert ;
Bauer, Martin ;
Karch, Rudolf ;
Lubberink, Mark ;
Pataraia, Ekaterina ;
Joukhadar, Christian ;
Kletter, Kurt ;
Lammertsma, Adriaan A. ;
Baumgartner, Christoph ;
Mueller, Markus ;
Langer, Oliver .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (01) :116-123
[2]  
*AV PHARM INC, 2007, TAR XR9576 P GLYC PU
[3]   Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET [J].
Bankstahl, Jens P. ;
Kuntner, Claudia ;
Abrahim, Aiman ;
Karch, Rudolf ;
Stanek, Johann ;
Wanek, Thomas ;
Wadsak, Wolfgang ;
Kletter, Kurt ;
Mueller, Markus ;
Loescher, Wolfgang ;
Langer, Oliver .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (08) :1328-1335
[4]   A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier [J].
Bankstahl, Jens P. ;
Bankstahl, Marion ;
Kuntner, Claudia ;
Stanek, Johann ;
Wanek, Thomas ;
Meier, Martin ;
Ding, Xiao-Qi ;
Mueller, Markus ;
Langer, Oliver ;
Loescher, Wolfgang .
JOURNAL OF NEUROSCIENCE, 2011, 31 (24) :8803-8811
[5]   Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET [J].
Bart, J ;
Willemsen, ATM ;
Groen, HJM ;
van der Graaf, WTA ;
Wegman, TD ;
Vaalburg, W ;
de Vries, EGE ;
Hendrikse, NH .
NEUROIMAGE, 2003, 20 (03) :1775-1782
[6]   ABCB1 pharmacogenetics:: Progress, pitfalls, and promise [J].
Chinn, L. W. ;
Kroetz, D. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :265-269
[7]   Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier [J].
Choo, Edna F. ;
Kurnik, Daniel ;
Muszkat, Mordechai ;
Ohkubo, Tadashi ;
Shay, Sheila D. ;
Higginbotham, James N. ;
Glaeser, Hartmut ;
Kim, Richard B. ;
Wood, Alastair J. J. ;
Wilkinson, Grant R. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (03) :1012-1018
[8]   Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier [J].
Cutler, Leanne ;
Howes, Colin ;
Deeks, Nigel J. ;
Buck, Tania L. ;
Jeffrey, Phil .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (09) :1944-1953
[9]   Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs [J].
Doan, KMM ;
Humphreys, JE ;
Webster, LO ;
Wring, SA ;
Shampine, LJ ;
Serabjit-Singh, CJ ;
Adkison, KK ;
Polli, JW .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1029-1037
[10]   Regional P-Glycoprotein Activity and Inhibition at the Human Blood-Brain Barrier as Imaged by Positron Emission Tomography [J].
Eyal, S. ;
Ke, B. ;
Muzi, M. ;
Link, J. M. ;
Mankoff, D. A. ;
Collier, A. C. ;
Unadkat, J. D. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) :579-585